Alteration in fasting glucose after prolonged treatment with a thiazide diuretic

Diabetes Research and Clinical Practice

Volumn 104, Issue 3, 2014, Pages 363-369

  Karnes, Jason H ^a   Gong, Yan ^b   Arwood, Meghan J ^b   Gums, John G ^b,c   Hall, Karen L ^c   Limacher, Marian C ^c   Johnson, Julie A ^b,c   Cooper DeHoff, Rhonda M ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Chlorthalidone; Glucose; Hydrochlorothiazide; Hypertension; Thiazide diuretics; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; TREATMENT DURATION;

CHLORTHALIDONE; GLUCOSE; HYDROCHLOROTHIAZIDE; HYPERTENSION; THIAZIDE DIURETICS; Β BLOCKERS;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS; DIURETICS; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84902544259     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.004     Document Type: Article

References (21)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
2. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
3. Karnes J.H., Cooper-DeHoff R.M. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009, 7:689-702.
4. Nandeesha H., Pavithran P., Madanmohan T. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men. Angiology 2009, 60:217-220.
5. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
6. Rajala U., Qiao Q., Laakso M., Keinanen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2000, 50:231-239.
7. Alderman M.H., Cohen H., Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999, 33:1130-1134.
8. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013, 31:1281-1357.
9. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
10. Gupta A.K., Dahlof B., Dobson J., Sever P.S., Wedel H., Poulter N.R. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008, 31:982-988.
11. Lind L., Pollare T., Berne C., Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994, 128:1177-1183.
12. Barzilay J.I., Davis B.R., Cutler J.A., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
13. Johnson J.A., Boerwinkle E., Zineh I., et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009, 157:442-449.
14. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl 1):S64-S71.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf 2009, 42:377-381.
17. Nichols G.A., Hillier T.A., Brown J.B. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008, 121:519-524.
18. Tirosh A., Shai I., Tekes-Manova D., et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005, 353:1454-1462.
19. Duarte J.D., Cooper-DeHoff R.M. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010, 8:793-802.
20. Cooper-Dehoff R.M., Bird S.T., Nichols G.A., Delaney J.A., Winterstein A.G. Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. J Am Heart Assoc 2013, 2:e000125.
21. Maitland-van der Zee A.H., Turner S.T., Schwartz G.L., Chapman A.B., Klungel O.H., Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005, 18:1077-1083.